From: Outcomes of Cardiac Resynchronization Therapy in Patients with Hypothyroidism and Heart Failure
Variable | Univariate Analysis | Multivariate Analysis | ||||
---|---|---|---|---|---|---|
HR | 95% CI | P Value | HR | 95% CI | P Value | |
Age | 0.99 | 0.98–1.00 | 0.08 |  |  |  |
Female | 0.41 | 0.29–0.59 | < 0.001 | 0.45 | 0.27–0.75 | 0.002 |
Primary prevention | 0.54 | 0.40–0.72 | < 0.001 | 0.28 | 0.10–0.83 | 0.02 |
Hypertension | 1.04 | 0.81–1.32 | 0.78 |  |  |  |
Diabetes mellitus | 1.01 | 0.78–1.32 | 0.92 |  |  |  |
Chronic kidney disease | 1.24 | 0.94–1.63 | 0.13 |  |  |  |
Hyperlipidemia | 1.09 | 0.86–1.39 | 0.48 |  |  |  |
Atrial fibrillation | 1.20 | 0.94–1.53 | 0.14 |  |  |  |
ICM | 1.13 | 0.89–1.44 | 0.32 |  |  |  |
LBBB | 0.67 | 0.52–0.85 | 0.001 | 0.72 | 0.50–1.05 | 0.08 |
QRS duration | 0.997 | 0.992–1.001 | 0.17 |  |  |  |
NYHA functional class | 1.16 | 0.91–1.47 | 0.24 |  |  |  |
LVEF | 0.98 | 0.96–1.00 | 0.02 | 0.97 | 0.95–1.01 | 0.11 |
TRT | 0.97 | 0.71–1.32 | 0.84 |  |  |  |
Statin | 1.02 | 0.80–1.30 | 0.87 |  |  |  |
amiodarone | 1.62 | 1.22–2.15 | 0.001 | 0.44 | 0.16–1.27 | 0.13 |
Digoxin | 1.55 | 1.22–1.97 | < 0.001 | 1.44 | 1.00–2.07 | 0.05 |
ACEARB | 0.77 | 0.57–1.05 | 0.09 | 0.73 | 0.45–1.18 | 0.20 |
Aldactone | 1.07 | 0.82–1.38 | 0.62 |  |  |  |
Furosemide | 1.30 | 0.99–1.71 | 0.06 | 1.13 | 0.75–1.70 | 0.54 |
CRT response | 0.43 | 0.32–0.59 | < 0.001 | 0.46 | 0.32–0.68 | < 0.001 |
TSH per 5 mIU/L | 1.05 | 1.02–1.09 | 0.002 | 1.23 | 1.01–1.50 | 0.04 |